Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment by Elizabeth S. Munroe, Greg A. Grandits, Robert C. Hyzy, Hallie C. Prescott, Thomas W. Barrett, Robin L. Dewar, Nicole Engen, Anna L. Goodman, Timothy J. Hatlen, Helene Highbarger, Thomas L. Holland, Gareth Hughes, Tomas O. Jensen, Muhammad A. Khan, Ioannis Kalomenidis, Nayon Kang, Sylvain Laverdure, Prasad Manian, Vidya Menon, Ravi Patel, Srikanth Ramachandruni, Tauseef Rehman, Kathryn Shaw-Saliba, Birgit Thorup Røge, David M. Vock, Amy C. Weintrob, Barnaby E. Young, Anne P. Frosch, for the STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups

Get full text

Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. by Elizabeth S Munroe, Greg A Grandits, Robert C Hyzy, Hallie C Prescott, Thomas W Barrett, Robin L Dewar, Nicole Engen, Anna L Goodman, Timothy J Hatlen, Helene Highbarger, Thomas L Holland, Gareth Hughes, Tomas O Jensen, Muhammad A Khan, Ioannis Kalomenidis, Nayon Kang, Sylvain Laverdure, Prasad Manian, Vidya Menon, Ravi Patel, Srikanth Ramachandruni, Tauseef Rehman, Kathryn Shaw-Saliba, Birgit Thorup Røge, David M Vock, Amy C Weintrob, Barnaby E Young, Anne P Frosch, STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups

Get full text